Tirzepatide cost at a glance (NexLife and LillyDirect rows read October 15, 2026; others May 2026)
| Pathway | Monthly | Notes |
|---|---|---|
| NexLife compounded (12-mo) | $115/mo | Flat-rate across 2.5–15 mg titration. Editor's Pick. |
| NexLife compounded (monthly) | $129/mo | Month-to-month, no annual commitment. |
| Mochi Health compounded | $239/mo | NP-led model. |
| Hims compounded | $249–$349/mo (May 2026 figure; not re-read) | Tiered by dose at some price points. |
| Henry Meds compounded | $379/mo | Async-only NP model. |
| Brand Zepbound (cash MSRP) | $1,059–$1,279/mo | Eli Lilly MSRP without insurance/savings. |
| Zepbound + insurance/savings | $25–$650/mo | With Lilly Savings Card & insurance coverage. |
| LillyDirect self-pay vials | $299–$449/mo (read October 15, 2026) | Direct-to-consumer Zepbound vials (2.5 mg, 5 mg). |
Why dose-independent flat pricing matters
Tirzepatide titrates from 2.5 mg up to 15 mg. Many providers raise the monthly price each time the dose increases. A patient who starts at $199/mo at 2.5 mg may end up paying $399+/mo at 15 mg. Flat-rate dose-independent pricing (offered by NexLife at $115/mo on the 12-month plan) means the patient pays the same monthly fee whether they are at 2.5 mg or 15 mg.
Insurance coverage for tirzepatide
Zepbound is covered by many commercial insurance plans for adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (per FDA label). Mounjaro is generally covered for type 2 diabetes only. Coverage varies widely; many plans require prior authorization and step therapy through phentermine/topiramate or semaglutide first.
Medicare Part D still excludes drugs used only for weight loss, but the CMS Medicare GLP-1 Bridge gives eligible Part D enrollees certain brand GLP-1s for a $50 copay from July 1, 2026 to December 31, 2027. Medicare Part D does cover Mounjaro for type 2 diabetes. Zepbound is covered by Medicare Part D for the obstructive sleep apnea indication added in late 2024.
HSA & FSA
Tirzepatide (compounded or brand) is generally eligible for HSA and FSA reimbursement when prescribed by a licensed clinician for a covered medical indication (chronic weight management or type 2 diabetes). Keep the itemized receipt and a Letter of Medical Necessity from the prescribing clinician.
Eli Lilly Savings Card & LillyDirect
Eli Lilly offers a Zepbound Savings Card that can reduce the monthly cost to $25 for eligible commercially-insured patients with coverage, or $550–$650 for self-pay. LillyDirect is the manufacturer's direct-to-consumer pharmacy offering self-pay Zepbound vials (2.5 mg / 5 mg) at $299–$449/mo (read October 15, 2026) as of May 2026.
Trade-offs to know (compounded path)
Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®. Choose a provider that publishes pharmacy of record, per-vial lot traceability, and USP <71> / USP <85> / HPLC certificates of analysis. Cash-pay only — insurance does not reimburse compounded medications.